European VC firms band together to tackle continent’s lacklustre capital
European venture capital (VC) firms have joined forces to establish the European Life Sciences Coalition (ELSC), the latest move by …
Post
-
-
Preclinical model drawbacks dampen UK innovation, ABPI report says
A report from the Association of the British Pharmaceutical Industry (ABPI) has suggested that a disharmony between academia and industry …
-
Significant opportunities exist in the global pain market for novel mechanisms and modalities
Pain is a multifaceted, highly heterogeneous disorder that is treated using analgesics. There is a lack of diversity within the …
-
Ampersand Capital acquires Purna Pharmaceuticals
Ampersand Capital Partners has acquired Purna Pharmaceuticals, a Belgium-based provider of development and manufacturing services for liquid and semi-solid dosage …
-
Amgen receives EC approval for Uplizna in generalised myasthenia gravis
Amgen has secured approval from the European Commission (EC) for Uplizna (inebilizumab) as an add-on treatment to standard therapy for …
-
Market instability expected from South Korea’s new pricing reform in 2026-2028
Every two years, South Korea adjusts the national health insurance (NHI) prices for existing listed products based on the actual …
-
Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head
Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi, after the French vaccine specialist announced it …
-
Madrigal expands MASH pipeline in $4.4bn siRNA licensing deal
Madrigal Pharmaceuticals has inked a deal worth up to $4.4bn with Chinese biotech Suzhou Ribo Life Science and its subsidiary …
-
Citius Oncology and Uniphar sign European distribution deal for Lymphir
Citius Pharmaceuticals' subsidiary Citius Oncology has signed an exclusive distribution agreement with Uniphar to enable access to Lymphir (denileukin diftitox-cxdl) …
-
MSD receives FDA approval for Keytruda combo to treat ovarian cancer
MSD has received the US Food and Drug Administration (FDA) approval for Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase …
-
Mexico enlists Moderna to boost mRNA supply for respiratory diseases
The Mexican Government has struck a long-term agreement with Moderna that will see the drugmaker help the country boost its …
-
FDA declines to review Moderna’s seasonal flu mRNA vaccine
The US Food and Drug Administration (FDA) has refused to review Moderna’s seasonal influenza jab, mRNA-1010, as the shifting vaccine …
-
Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target
Gilead said it expects sales for its HIV portfolio to increase 6% in 2026 compared to 2025, spearheaded by growth …
-
THX Pharma and Biocodex sign licensing deal for Batten-1 and TX01 drugs
THX Pharma (Theranexus) and Biocodex have entered a strategic licensing agreement to further the development of two drug candidates, Batten-1 …
-
Insilico and CMS launch drug discovery collaborations for CNS diseases
Insilico Medicine has announced several AI drug discovery collaborations with China Medical System (CMS) across several projects in central nervous …
